# Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)

> **NCT01747577** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 68 (actual)

## Conditions studied

- Overactive Bladder
- Benign Prostate Hyperplasia
- Transurethral Resection of Prostate
- Photoselective Vaporization Prostatectomy

## Interventions

- **DRUG:** Solifenacin Succinate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01747577
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-04
- **Primary completion:** 2013-10-24
- **Final completion:** 2013-10-24
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747577, "Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01747577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*